// App-Quantinova.ai

: Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma

Researchers

Presenter

  • Yuta Ito

Principal Investigators

  • Yasunori Kogure

  • Junji Koya

  • Mariko Tabata

  • Yuki Saito

  • Sumito Shingaki

  • Mitsuhiro Yuasa

  • Kentaro Yamaguchi

  • Julie Bruneau

  • Manon Vavasseur

  • Michael Dussiot

  • Isabelle André

  • Akshay Joshi

  • Chantal Lagresle-Peyrou

  • Aude Magerus

  • Sammara CHAUBARD

  • David Lavergne

  • Emmanuel Bachy

  • Erika Brunet

  • Virginie Fataccioli

  • Chantal Brouzes

  • Camille Laurent

  • Laurence de Leval

  • Alexandra Traverse-Glehen

  • Celine Bossard

  • Marie Parrens

  • Veronique Meignin

  • Laure Philippe

  • Julien Rossignol

  • Felipe Suarez

  • Jean-Marie Michot

  • Olivier Tournilhac

  • Christine Bole-Feysot

  • Patrick Nitschke

  • Bruno Tesson

  • Cecile Laurent

  • Thierry Jo Molina

  • Vahid Asnafi

  • Sachiko Tsukita

  • Koji Izutsu

  • Hiroaki Miyoshi

  • Seiji Sakata

  • Akito Dobashi

  • Kengo Takeuchi

  • Koichi Ohshima

  • Philippe Gaulard

  • Arnaud Jaccard

  • Seishi Ogawa

  • Olivier Hermine

  • Keisuke Kataoka

  • Lucile Couronne

Medical Centers

  • Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan

  • Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

  • Hematology Department, Necker Children's Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France

  • Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

  • Advanced Comprehensive Research Organization (ACRO), Teikyo University, Toko, Japan

  • Department of Pathology, Kurume University School of Medicine, Kurume, Japan

  • Department of Hematology, Toranomon Hospital, Tokyo, Japan

  • Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  • Department of Hematology, CH Annecy Genevois, Metz-Tessy, France

  • Bioinformatics department, CALYM / LYSARC, Paris, France

  • Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France; Cancer Research Center of Toulouse, INSERM UMR , ERL CNRS, Université Toulouse III-Paul-Sabatier, Toulouse, France

  • Department of Pathology, Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-, Pierre- Bénite, France

  • Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute, INSERM UMR , Paris City University, Paris, France

  • Genomics Core Facility, Institut Imagine-Structure Fédérative de Recherche Necker, INSERM U et INSERM US/CNRS UAR, Paris City University, Paris, France

  • Laboratory of Human Lympho Hematopoiesis, INSERM UMR , Clinical Investigation Center (CIC) -Institut Imagine, Paris City University, Paris, France

  • Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

  • INSERM U, Institut Necker Enfants Malades (INEM), Paris, France

  • Gustave Roussy, Département des Innovations Thérapeutiques et Essais Précoces, Université Paris-Saclay, Villejuif, France

  • Hematology Department, Hospices Civils de Lyon; Lymphoma Immuno-Biology (LIB) Team, Université Claude Bernard Lyon , Lyon, France

  • Pathology Department, Hôpital Saint Louis, Paris City University, Paris, France

  • Pathology Department, Henri Mondor University Hospital, Assistance Publique des Hôpitaux de Paris, INSERM U, Mondor Institute for Biomedical Research, Paris-Est Créteil University, Créteil, France

  • Hematology department, Limoges University Hospital, Limoges, France

  • Center for Hematology and Regenerative Medicine, Department of Medicine (MedH), Karolinska Institutet, Huddinge, Sweden

  • Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM U, Imagine Institute, Paris City University, Paris, France

  • Department of Gastroenterology, Keio University School of Medicine, Tokyo, Japan

  • Department of Pathology, CHU Nantes, Nantes, France; Université de Nantes, INSERM CRCINA, Nantes, France

  • Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

  • INSERM Unité Mixte de Recherche , Bioinformatics Platform, Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France

  • Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland

  • Department of Pathology, Bordeaux University Hospital, Bordeaux, France

  • Department of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan

  • Laboratory of the « Genome Dynamics in the Immune System », Équipe Labellisée La Ligue Contre Le Cancer, Paris City University, Université Paris Saclay, INSERM UMR , Institut Imagine, Paris, Falkland Islands (The) [Malvinas]

  • National Cancer Center Hospital, Tokyo, Japan

  • Department of Hematology, University Hospital of Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France

Locations

  • Japan

  • France

  • Switzerland

  • Sweden

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • T-cell lymphoma

  • Solid malignancies

Biomarkers

  • AT-rich interactive domain 1A

  • Natural Killer cells

  • Dual specificity mitogen-activated protein kinase kinase 1

  • Calcitonin

  • Cyclin Dependent Kinase Inhibitor 2A

  • Programmed death-ligand 1

  • Major Histocompatibility Complex, Class I, A

  • Major Histocompatibility Complex, Class I, B

  • Janus kinase 3

  • Apparent diffusion coefficient

  • Tumor protein p53

Drug/Treatment

  • Fuldazin

  • TP53

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved